Efficacy of tyrosine kinase inhibitors in non‑small‑cell lung cancer patients undergoing dose reduction and those with a low body surface area

Sato,Shinya; Kurishima,Koichi; Miyazaki,Kunihiko; Kodama,Takahide; Ishikawa,Hiroichi; Kagohashi,Katsunori; Tamura,Tomohiro; Homma,Shinsuke; Satoh,Hiroaki; Hizawa,Nobuyuki

doi:10.3892/mco.2014.281

Efficacy of tyrosine kinase inhibitors in non‑small‑cell lung cancer patients undergoing dose reduction and those with a low body surface area

Authors:
- Shinya Sato
- Koichi Kurishima
- Kunihiko Miyazaki
- Takahide Kodama
- Hiroichi Ishikawa
- Katsunori Kagohashi
- Tomohiro Tamura
- Shinsuke Homma
- Hiroaki Satoh
- Nobuyuki Hizawa
View Affiliations

Affiliations: Division of Respiratory Medicine, Ryugasaki Saiseikai General Hospital, Ryugasaki, Ibaraki 301‑0854, Japan, Division of Respiratory Medicine, Faculty of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki 305‑8575, Japan, Division of Respiratory Medicine, Tsukuba Medical Center Hospital and Regional Cancer Center, Tsukuba, Ibaraki 305‑8558, Japan, Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310‑0015, Japan
Published online on: April 16, 2014 https://doi.org/10.3892/mco.2014.281
Pages: 604-608

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of this study was to evaluate the efficacy of epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) in patients undergoing dose reduction and in those with a low body surface area (BSA). The association between dose reduction, low BSA and efficacy, including response rate (RR), disease control rate (DCR), progression‑free survival (PFS) and overall survival (OS), were evaluated in patients prescribed TKIs between September, 2002 and May, 2013. A total of 282 patients received EGFR‑TKIs during the study period, 53 (18.8%) of whom underwent a dose reduction (21.4 and 31.6% of the patients with a BSA of <1.5 and <1.25 m2, respectively). Eleven (20.8%) of these 53 patients had a dose reduction due to adverse events (AEs) >grade 3. In either gefitinib or erlotinib treatment, the RR, DCR, PFS and OS in EGFR‑mutated patients with a BSA of <1.5 m2 were not different from those in patients with a BSA of >1.5 m2. In addition, there were no differences in these parameters between patients with and those without a dose reduction of TKIs. The dose of TKIs in patients with AEs and in those with low BSA should be determined with caution. To confirm the equal efficacy of TKIs in patients undergoing a dose reduction, prospective observational studies with less patient heterogeneity are required.

View Figures

View References

1	Seymour L and Eisenhauer E: A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity. Cancer Chemother Pharmacol. 47:2–10. 2001. View Article : Google Scholar : PubMed/NCBI
2	Hoekstra R, Verweij J and Eskens FA: Clinical trial design for target specific anticancer agents. Invest New Drugs. 21:243–250. 2003. View Article : Google Scholar : PubMed/NCBI
3	Zohar S, Lian Q, Levy V, Cheung K, Ivanova A and Chevret S: Quality assessment of phase I dose-finding cancer trials: proposal of a checklist. Clin Trials. 5:478–485. 2008. View Article : Google Scholar : PubMed/NCBI
4	Wolf M, Swaisland H and Averbuch S: Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res. 10:4607–4613. 2004. View Article : Google Scholar : PubMed/NCBI
5	Takimoto CH: Maximum tolerated dose: clinical endpoint for a bygone era? Target Oncol. 4:143–147. 2009. View Article : Google Scholar : PubMed/NCBI
6	Yamamoto N, Horiike A, Fujisaka Y, et al: Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol. 61:489–496. 2008. View Article : Google Scholar : PubMed/NCBI
7	Boyer M, Horwood K, Pavlakis N, et al: Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study. Asia Pac J Clin Oncol. 8:248–254. 2012. View Article : Google Scholar : PubMed/NCBI
8	Gahr S, Stoehr R, Geissinger E, et al: EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer. 109:1821–1828. 2013. View Article : Google Scholar : PubMed/NCBI
9	Kaburagi T, Satoh H, Hayashihara K, et al: Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer. Oncol Lett. 5:435–439. 2013.PubMed/NCBI
10	Ichihara E, Hotta K, Takigawa N, et al: Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer. 81:435–439. 2013. View Article : Google Scholar : PubMed/NCBI
11	Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC: Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC Press; Lyon: pp. 9–122. 2004
12	Kligerman S and Abbott G: A radiologic review of the new TNM classification for lung cancer. AJR Am J Roentgenol. 194:562–573. 2010. View Article : Google Scholar : PubMed/NCBI
13	Sohaib A: RECIST rules. Cancer Imaging. 12:345–346. 2012. View Article : Google Scholar
14	Pennell NA: Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 12:350–359. 2011. View Article : Google Scholar : PubMed/NCBI
15	Roengvoraphoj M, Tsongalis GJ, Dragnev KH and Rigas JR: Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treat Rev. 39:839–850. 2013. View Article : Google Scholar
16	Hayashibara K, Satoh H, Shinohara Y, et al: A population-based study of gefitinib in patients with non-small cell lung cancer. Med Oncol. 26:222–227. 2009. View Article : Google Scholar : PubMed/NCBI
17	Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 28:3239–3247. 2010. View Article : Google Scholar : PubMed/NCBI
18	Wittenburg LA and Gustafson DL: Optimizing preclinical study design in oncology research. Chem Biol Interact. 190:73–78. 2011. View Article : Google Scholar : PubMed/NCBI
19	Fujita KI and Sasaki Y: Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in ‘clinical trials’ to those in the ‘real world’. Drug Metab Pharmacokinet. 29:20–28. 2014.
20	Fukudo M, Ikemi Y, Togashi Y, et al: Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clin Pharmacokinet. 52:593–609. 2013. View Article : Google Scholar
21	Ranson M and Wardell S: Gefitinib, a novel, orally administered agent for the treatment of cancer. J Clin Pharm Ther. 29:95–103. 2004. View Article : Google Scholar : PubMed/NCBI